Cardiovascular Complications of HIV Infection and Treatment

Author(s): Himanshu Garg, Anjali Joshi, Debabrata Mukherjee

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Volume 11 , Issue 1 , 2013

Become EABM
Become Reviewer
Call for Editor


With improved and highly active antiretroviral therapy (HAART) the average life span of HIV infected individuals has increased tremendously. HIV infections can now be managed with HAART for years making it a chronic disease much in line with others like diabetes or high blood pressure. However the increasing use of HAART therapy for HIV management has also revealed a growing concern for the side effects associated with this treatment regimen. The two groups of drugs currently at the forefront of HAART therapy namely Nucleoside Reverse Transcriptase inhibitors (NRTI) and Protease inhibitors (PI) are known to induce toxicities that lead to cardiovascular complications. While NRTIs are known to directly affect cardiac cells via their effect on mitochondria; the PIs have more indirect effects through alteration of lipid metabolism leading to dyslipidemia, a predisposing factor for atherosclerosis and heart disease. In this review, we provide a summary of the mechanism of cardiovascular complications that are associated with HIV infection as well as long term treatment with HAART.

Keywords: Adverse events, cardiovascular disease, drug toxicity, dyslipidemia, HAART, HIV, infectious diseases, mitochondria, protease inhibitors, reverse transcriptase inhibitors, virus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 06 January, 2013
Page: [58 - 66]
Pages: 9
DOI: 10.2174/1871525711311010010

Article Metrics

PDF: 42